Acne vulgaris
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients with acne vulgaris who have 10 or more inflammatory rashes on the trunk(Chest or bBack) 2) Patients who provided written informed consent after receiving an explanation of the details of the study 3) Patients aged 16 years old or older at the time informed consent was provided For patients younger than 20 years old, representatives (parents, etc.) are required to provide informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who had received treatment for acne vulgaris within one month of the start of the study 2) Patients in whom the study drug is contraindicated 3) Patients with continuous use of non-steroidal anti-inflammatory drugs (ibuprofen, etc.) 4) Pregnant women, those who may be pregnant, lactating women, and women who hope to become pregnant during the study period 5) Patients who were considered inappropriate for the study by an investigator 6) Patients who had participated in other clinical studies and phase IV clinical trials of drugs for acne vulgaris within 6 months of the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in the number of inflammatory rashes / during 12 weeks of observation period | — |
Countries
Japan
Contacts
EBC&M LLC. Project planning & Development department